Wages, Nolan A., Ph.D.

Dr. Wages is an Associate Professor in the Division of Translational Research & Applied Statistics in the Department of Public Health Sciences and the Co-Director of the Center for Early Phase Trials (CEPT). He is an active member of the UVA Cancer Center Biostatistics Shared Resource. Dr. Wages is part of a national research effort to change the way early-phase clinical trials in oncology are done, not only through the pursuit of novel statistical methods but also by focusing on the successful implementation of developed methods into real studies. He collaborates with cancer center members in tailoring clinical trial designs to meet contemporary research objectives in early drug development. Dr. Wages is the Principal Investigator of current NIH/NCI R01 funding entitled “Dose-finding designs for late-onset toxicities.”

Associate Professor
Translational Research & Applied Statistics
Ph.D., Statistics, University of Virginia, 2010

P.O. Box 800717
Tel: 1-434-924-8222
Fax: 1-434-243-5787
Email: nwages@virginia.edu
West Complex Old Med School Room 3890

Research Interests:

• Design, monitoring, and analysis of early-phase cancer clinical trials with interests in drug combination studies, patient heterogeneity, multiple treatment schedules, therapeutic cancer vaccines, late-onset toxicities, multiple endpoints, and adoptive cell immunotherapy.

Professional Service:

• Associate Editor, Clinical Trials.
• Faculty member, ASCO/AACR Methods in Clinical Cancer Research Workshop; Vail, CO.
• NIH/NCI Investigational Drug Steering Committee, Clinical Trial Design Task Force Working Group.

Teaching Responsibilities:

• PHS 7310 – Clinical Trials Methodology

Additional Resources:

• Designing and conducting contemporary early-phase clinical trials.

Selected Publications:

1. Wages NA, Slingluff CL, Jr. Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines. Stat Biosci 2020; 12: 104-123. PMCID: PMC7302057.
2. Wages NA, Fadul CE. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy. Clin Trials 2020; 17: 157-165. PMCID: PMC7211137.
3. Horton BJ, Wages NA, Conaway MR. Shift models for dose-finding in partially ordered groups. Clin Trials 2019; 16: 32-40. PMID: 30309262.
4. Yan D, Tait C, Wages NA, Kindwall-Keller T, Dressler EV. Generalization of the time-to-event continual reassessment method to bivariate outcomes. J Biopharm Stat 2019; 29: 635-647. PMCID: PMC6823630.
5. Conaway MR, Wages NA. Designs for phase I trials in ordered groups. Stat Med 2017; 36: 254-65. PMCID: PMC5140690.
6. Wages NA, Tait C. Seamless phase I/II adaptive design for oncology trials of molecularly targeted agents. J Biopharm Stat 2015; 25: 903-20. PMCID: PMC4363077.
7. Wages NA, O’Quigley J, Conaway MR. Phase I design for completely or partially ordered treatment schedules. Stat Med 2014; 33: 569-79. PMCID:  PMC3947103.
8. Wages NA, Conaway MR, O’Quigley J. Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med 2013; 32: 131-41. PMCID: PMC3521068.
9. Wages NA, Conaway MR, O’Quigley J. Continual reassessment method for partial ordering. Biometrics 2011; 67: 1555-63. PMCID: PMC3141101.

        A complete list of published work is available at MyBibliography and Google Scholar.